Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno D'Alcontres 31, I-98125 Messina, Italy.
Department of Organic Chemistry, University of Chemistry and Technology, Prague, 166 28 Prague, Czech Republic.
Int J Mol Sci. 2024 Oct 17;25(20):11174. doi: 10.3390/ijms252011174.
In the aging process, skin morphology might be affected by wrinkle formation due to the loss of elasticity and resilience of connective tissues linked to the cleavage of elastin by the enzymatic activity of elastase. Little information is available about the structural requirements to efficiently inhibit elastase 1 (EC 3.4.21.36) expressed in skin keratinocytes. In this study, a structure-based approach led to the identification to the pharmacophoric hypotheses that described the main structural requirements for binding to porcine pancreatic elastase as a valuable tool for the development of skin therapeutic agents due to its similarity with human elastase 1. The obtained models were subsequently refined through the application of computational alanine-scanning mutagenesis to evaluate the effect of single residues on the binding affinity and protein stability; in turn, molecular dynamic simulations were carried out; these procedures led to a simplified model bearing few essential features, enabling a reliable collection of chemical features for their interactions with elastase. Then, a virtual screening campaign on the in-house library of synthetic compounds led to the identification of a nonpeptide-based inhibitor (IC = 60.4 µM) belonging to the class of -substituted-1-benzimidazol-2-yl]thio]acetamides, which might be further exploited to obtain more efficient ligands of elastase for therapeutic applications.
在衰老过程中,由于与弹性蛋白裂解有关的弹性组织的弹性和弹性丧失,皮肤形态可能会受到皱纹形成的影响。关于有效抑制皮肤角质形成细胞中表达的弹性蛋白酶 1(EC 3.4.21.36)的结构要求的信息很少。在这项研究中,基于结构的方法导致了药效团假说的鉴定,这些假说描述了与猪胰弹性蛋白酶结合的主要结构要求,由于其与人弹性蛋白酶 1 的相似性,因此可作为开发皮肤治疗剂的有价值工具。获得的模型随后通过应用计算丙氨酸扫描诱变来进行细化,以评估单个残基对结合亲和力和蛋白质稳定性的影响;反过来,进行了分子动力学模拟;这些程序导致了一个简化的模型,仅具有几个基本特征,能够可靠地收集其与弹性蛋白酶相互作用的化学特征。然后,对内部合成化合物库进行虚拟筛选,鉴定出一种非肽类抑制剂(IC = 60.4 µM),属于取代的 1-苯并咪唑-2-基]硫代]乙酰胺类,可进一步开发用于治疗应用的更有效的弹性蛋白酶配体。